Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase EARLY_PHASE1 2Phase NA 1

Status

Active not recruiting 2Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Colonic Neoplasms 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 8Nivolumab 7Magnetic Resonance Spectroscopy 7Radiotherapy 6Biopsy 4Temozolomide 3Specimen Handling 3Irinotecan 3Ipilimumab 3Fluorodeoxyglucose F18 3Dexamethasone 3Bevacizumab 3venetoclax 2niraparib 2gallium 68 PSMA-11 2durvalumab 2avelumab 2Tobacco Use Cessation Devices 2Standard of Care 2Rituximab 2Positron-Emission Tomography 2Positron Emission Tomography Computed Tomography 2Paclitaxel 2Neoadjuvant Therapy 2Metastasectomy 2Immunoglobulin G 2FAPI-46 2Disulfides 2Cyclophosphamide 2Cetuximab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Active not recruiting × Metastasectomy × Clear all
NCT02210117 2026-06-01

Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery

M.D. Anderson Cancer Center

Phase EARLY_PHASE1 Active not recruiting
104 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT06011772 2026-03-11

EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer

Roswell Park Cancer Institute

Phase EARLY_PHASE1 Active not recruiting
2 enrolled
Gastrointestinal

Colonic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡